I think he’s actually being a sensible head, reading the announcement properly.
He’s not downramping for downramping’s sake.
The US data shows no difference to placebo for inflammatory lesions.
The Aussie data would send this to the moon.
We need an explanation as to why there’s a difference.
As a medical specialist, I can fathom why/how they’d use different controls in the two countries and then group the data. To me, it’s a poorly designed trial.
Ann: Botanix Announces BTX 1503 Data and Progression to Phase 3, page-269
-
- There are more pages in this discussion • 134 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
37.0¢ |
Change
0.015(4.23%) |
Mkt cap ! $669.7M | |||
| Open | High | Low | Value | Volume |
| 36.0¢ | 37.5¢ | 35.5¢ | $1.465M | 4.001M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 186321 | 36.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 37.5¢ | 561591 | 7 |
View Market Depth
| Last trade - 16.10pm 14/08/2024 (20 minute delay) ? |
| BOT (ASX) Chart |